BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 26211367)

  • 1. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Steeghs N; Nortier JW; Gelderblom H
    Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.
    Yin Y; Yuan X; Gao H; Yang Q
    Int J Pharm; 2020 Jan; 573():118785. PubMed ID: 31678384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tyrosine kinases as molecular targets to inhibit cancer progression and metastasis.
    Cepero V; Sierra JR; Giordano S
    Curr Pharm Des; 2010; 16(12):1396-409. PubMed ID: 20166985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A historical overview of protein kinases and their targeted small molecule inhibitors.
    Roskoski R
    Pharmacol Res; 2015 Oct; 100():1-23. PubMed ID: 26207888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J; Hochwald SN
    Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antineoplastic agents targeting tyrosine kinases].
    Guren TK; Christoffersen T; Thoresen GH; Wisløff F; Dajani O; Tveit KM
    Tidsskr Nor Laegeforen; 2005 Nov; 125(22):3115-9. PubMed ID: 16299568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).
    Huang L; Jiang S; Shi Y
    J Hematol Oncol; 2020 Oct; 13(1):143. PubMed ID: 33109256
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted therapies for solid tumors: current status and future perspectives.
    Stoffel A
    BioDrugs; 2010 Oct; 24(5):303-16. PubMed ID: 20649180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
    Levitzki A; Klein S
    Proc Natl Acad Sci U S A; 2019 Jun; 116(24):11579-11586. PubMed ID: 31076554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Receptor tyrosine kinases and targeted cancer therapeutics.
    Takeuchi K; Ito F
    Biol Pharm Bull; 2011; 34(12):1774-80. PubMed ID: 22130229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
    Jiang W; Ji M
    Semin Cancer Biol; 2019 Dec; 59():3-22. PubMed ID: 30943434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors.
    Natoli C; Perrucci B; Perrotti F; Falchi L; Iacobelli S;
    Curr Cancer Drug Targets; 2010 Aug; 10(5):462-83. PubMed ID: 20384577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Small Molecule Tyrosine Kinases by Polyphenols: New Move Towards Anti-tumor Drug Discovery.
    Sakle NS; More SA; Dhawale SA; Mokale SN
    Curr Drug Discov Technol; 2020; 17(5):585-615. PubMed ID: 31393251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.